CBS 2019
CBSMD教育中心
English

Congestive Heart Failure

科研文章

荐读文献

Cardiovascular Aging and Heart Failure: JACC Review Topic of the Week Heart Failure With Preserved Ejection Fraction in the Young Dapagliflozin for treating chronic heart failure with reduced ejection fraction The Management of Atrial Fibrillation in Heart Failure: An Expert Panel Consensus Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry Lateral Wall Dysfunction Signals Onset of Progressive Heart Failure in Left Bundle Branch Block Association of Reduced Apical Untwisting With Incident HF in Asymptomatic Patients With HF Risk Factors Clinical epidemiology of heart failure with preserved ejection fraction (HFpEF) in comparatively young hospitalized patients Seattle Heart Failure and Proportional Risk Models Predict Benefit From Implantable Cardioverter-Defibrillators Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure

Review Article2020 May 28.

JOURNAL:Heart Fail Rev. Article Link

The Management of Atrial Fibrillation in Heart Failure: An Expert Panel Consensus

D Farmakis, C Chrysohoou, G Giamouzis et al. Keywords: AF; direct oral anticoagulants; HF; non-vitamin k antagonist oral anticoagulants; rate control; rhythm control

ABSTRACT

Heart failure (HF) and atrial fibrillation (AF) often coexist, being closely interrelated as the one increases the prevalence and incidence and worsens the prognosis of the other. Their frequent coexistence raises several challenges, including under-diagnosis of HF with preserved ejection fraction in AF and of AF in HF, characterization and diagnosis of atrial cardiomyopathy, target and impact of rate control therapy on outcomes, optimal rhythm control strategy in the era of catheter ablation, HF-related thromboembolic risk and management of anticoagulation in patients with comorbidities, such as chronic kidney disease or transient renal function worsening, coronary artery disease or acute coronary syndromes, valvular or structural heart disease interventions and cancer. In the present document, derived by an expert panel meeting, we sought to focus on the above challenging issues, outlining the existing evidence and identifying gaps in knowledge that need to be addressed.